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D
iabetes is at epidemic proportions
in the U.S. Patients with diabetes
are at increased risk for micro- and
macrovascularcomplications.Thebeneﬁt
of glycemic control in decreasing the risk
for microvascular disease is well estab-
lished. However, the role of glycemic
control in decreasing macrovascular
complications has been controversial.
Several large clinical trials looking at this
issuehaveeithershownnobeneﬁtoreven
potential harm. The possibility of hypo-
glycemiaasariskfactorforcardiovascular
events is a topic of much debate. In this
reviewarticle,wediscusstheevidencefor
and against this hypothesis and the pos-
sible mechanisms that might be involved.
Patients with diabetes have an in-
creased risk of cardiovascular disease.
The link between glycemic control and
microvascular complications has been
ﬁrmly established (1,2). However, the as-
sociation between glycemic control and
macrovascular disease is mainly obtained
from epidemiological studies, and inten-
sive glucose control has often failed to re-
duce macrovascular events. Intensive
glucose control invariably increases the risk
of hypoglycemia and sometimes the sever-
ity of hypoglycemia (2) Several epidemio-
logical studies and smaller prospective
studies have linked hypoglycemia to in-
creased cardiovascular risk (3–5). Recent
large randomized trials looking at inten-
sive glycemic control have either shown
no beneﬁt (Action in Diabetes and Vascu-
larDisease:PreteraxandDiamicronMod-
iﬁed Release Controlled Evaluation
[ADVANCE] and Veterans Affairs Diabe-
tes Trial [VADT]) or increased all cause
mortality (Action to Control Cardiovas-
cular Risk in Diabetes [ACCORD]) (6).
While the reason for the increased mor-
talityisunclearandhypoglycemiahasnot
been implicated as a cause of death, these
studies have increased the debate about
thedegreeofglycemiccontrolrequiredto
decrease diabetes complications and the
role of hypoglycemia in cardiovascular
morbidity and mortality.
DEFINITION, INCIDENCE
OF, AND RISK FACTORS
ASSOCIATED WITH
HYPOGLYCEMIA— The modern
deﬁnition of hypoglycemia is plasma glu-
cose 70 mg/dl (7–9). At plasma glucose
below this threshold (60–65 mg/dl), the
brain becomes neuroglycopenic and pro-
motessecretionofcounterregulatoryhor-
mones, primarily the adrenomedullary
adrenaline and the neurotransmitter nor-
epinephrine (along with glucagons, the
“rapid” responses), which have relevant
cardiovasculareffects(9–11).Thisoccurs
in the absence of the warning symptoms
of hypoglycemia, which normally occur
at lower plasma glucose (60 mg/dl) (9).
If (even mild) hypoglycemia episodes re-
cur often over time (e.g., once a day), the
brain adapts to hypoglycemia with symp-
tom responses at a lower-than-usual
plasma glucose concentration (9). This
shifting of brain glucose thresholds to
higher levels (i.e., it takes a lower plasma
glucose to activate symptom responses) is
dangerous because it masks most of the
mild hypoglycemia episodes until blood
glucose decreases to 50 mg/dl. In turn,
failuretosensesymptomsofhypoglyce-
mia in an early phase (hypoglycemia
unawareness) increases the risk of pro-
longing duration and increasing fre-
quency of hypoglycemia. These events
perpetrate a deleterious vicious circle
leading to an increase in severe hypogly-
cemia with brain dysfunction (9,11). The
response of adrenaline (and norepineph-
rine) in individuals with hypoglycemia
unawareness is lower than in aware sub-
jects (9), a ﬁnding that might be of car-
diovascular protection.
The incidence of hypoglycemia is
quite varied in the literature (supplemen-
taryTable1,availableinanonlineappen-
dix at http://care.diabetesjournals.org/
cgi/content/full/dc09-2082/DC1) (12),
with lack of standardization of deﬁnition
of hypoglycemia and its classiﬁcation.
Theincidenceofhypoglycemiainvarious
trials reviewed in this article depends on
the deﬁnitions of mild, moderate, and se-
vere hypoglycemia. Most recent large tri-
als have deﬁned severe hypoglycemia as
severe, whenever help from a third party
is required, whereas mild episodes are
thosethatareself-treated(supplementary
Table 1 reports severe episodes).
Hypoglycemia has long been recog-
nized as a major barrier to achieving nor-
moglycemia with intensive therapy and
hasthereforebeeninvestigatedintermsof
its impact (particularly on cognitive func-
tion)andphysiologicalcounterregulation
(7,11). In the Diabetes Control and Com-
plications Trial (DCCT), patients in the
intensive arm had a 65% incidence of se-
vere hypoglycemia, compared with 35%
in the conventional group (2,13). In the
UK Diabetes Prospective Study, the rates
of major hypoglycemic episodes were
0.7% in the conventional group, 1.4% in
the glibenclamide group, and 1.8% in the
group treated with insulin (1). In the 4-T
study, median rates of hypoglycemia per
patient per year were lowest in the basal
insulingroup(1.7),higherinthebiphasic
aspart insulin group (3.0), and highest in
the prandial aspart insulin group (5.7)
(14). An observational study of 383 pa-
tients reported that the duration of diabe-
tes and the duration of insulin treatment
were both positively correlated to hypo-
glycemicepisodes(15).Thus,althoughin
general in type 2 diabetes there is less hy-
poglycemia risk versus type 1 diabetes,
the frequency of hypoglycemia increases
with increased diabetes and insulin treat-
ment duration in type 2 diabetes, ap-
proaching the ﬁgures of type 1 diabetes
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responses to hypoglycemia. A retrospec-
tive cohort study of Medicaid enrollees,
aged 65 years, who used insulin or sul-
fonylureas, identiﬁed 586 individuals
with an episode of serious hypoglycemia
(16). In this cohort, recent hospital dis-
chargewasthestrongestpredictorofsub-
sequent hypoglycemia.
Mild hypoglycemic events are more
common but less reported. One prospec-
tivestudyof267patientswithbothtype1
and type 2 diabetes reported 572 hypo-
glycemic events in 155 patients (17). Pa-
tients with type 1 diabetes had a mild
hypoglycemic event rate of 42.89 events/
patient/year and 1.15 severe hypoglyce-
mic events/patient/year compared with
16.37 mild events/patient/year and 0.35
severe events/patient/year in subjects
with type 2 diabetes. Predictors of diabe-
tes in this group included previous hypo-
glycemia and duration of insulin therapy.
A retrospective cross-sectional analysis in
1,055 patients with type 2 diabetes re-
vealed a prevalence of hypoglycemic
symptomsin12%ofdiet-treatedpatients,
16% of patients using oral agents, and
30% of patients on insulin (18). Risk fac-
tors for hypoglycemia included insulin
therapy,lowerA1Catfollow-up,younger
age, and report of hypoglycemia at base-
line visit (18).
The estimation of the incidence is
complicated by the occurrence of hypo-
glycemia unawareness, which by its very
naturemakesitimpossibletodetermine
true incidence. Furthermore, many pa-
tients in trials may take corrective ac-
tion to treat hypoglycemia in its early
stages, without blood glucose testing,
and may not record the occurrence of
hypoglycemia. Therefore, all the above
rates of hypoglycemia are likely to be
underestimates.
Well-known risk factors for the de-
velopment of hypoglycemia include exer-
cise,alcohol,olderage,renaldysfunction,
infection, decreased intake of energy, and
mental health issues, including dementia,
depression, and psychiatric illnesses. In
the ADVANCE trial, cognitive dysfunc-
tion increased the risk of hypoglycemia
(hazard ratio 2.1).
EPIDEMIOLOGICAL
EVIDENCE FOR THE
ASSOCIATION BETWEEN
HYPOGLYCEMIA AND
CARDIOVASCULAR
MORBIDITY— Recent studies such
as VADT and ACCORD have brought to
the forefront the question of the role of
hypoglycemia, if any, in increasing the
risk for cardiovascular events. There are
few studies looking at this question.
Broadly, they can be divided into studies
that look at the effect of hypoglycemia on
cardiac ischemia, arrhythmias, and cere-
bral ischemia.
MYOCARDIAL ISCHEMIA,
INFARCTION, AND
ARRHYTHMIAS— The earliest
study in 1932 reported chest pain consis-
tent with myocardial ischemia in two of
seventype1diabeticpatientswithknown
cardiovascular disease (19). However,
other similar studies failed to conﬁrm
these ﬁndings (3,5). More recently, in a
retrospective review of 14,670 patients
withcoronaryarterydisease,recruitedfor
the Bezaﬁbrate Infarction Prevention
study (a secondary prevention prospec-
tive multicenter randomized placebo-
controlled double-blind trial conducted
to assess the efﬁcacy of bezaﬁbrate in re-
duction of coronary events conducted in
Israel)overan8-yearmeanfollow-up,hy-
poglycemia (70 mg/dl) was a predictor
of increased all-cause mortality with a
hazard ratio of 1.84, but not of increased
coronary artery disease mortality (4). The
Veterans Affairs Cooperative Study on
Glycemic Control and Complications in
Type II Diabetes showed that more car-
diac events were documented in patients
afterinstitutionofintensiveglycemiccon-
trol versus standard control (32 vs. 20%)
(20). However, this was not signiﬁcantly
different, since the study was inade-
quately powered to study this question
(20). In contrast, in the Bypass Angio-
plasty Revascularization Investigation 2
Diabetes (BARI 2D) trial, although severe
hypoglycemia was more frequent in the
insulin-provision group (9.2%) than in
the insulin-sensitization group (5.9%),
major cardiovascular events were not sig-
niﬁcantly different (21).
A few studies using continuous elec-
trocardiogram monitoring and glucose
monitoring have been performed re-
cently. Desouza et al. (22) demonstrated
that of 54 episodes of hypoglycemia, 10
were associated with symptoms or elec-
trocardiogram evidence of ischemia,
whereas only one episode of chest pain
occurred during 59 episodes of hypergly-
cemia. Less studied is the “dead-in-bed”
syndrome, which is deﬁned as sudden
nocturnal death in type 1 diabetes. In one
study, 24 deaths of patients with type 1
diabetes under the age of 50 years were
studied (23). Two patients had irrevers-
iblehypoglycemicbraindamageanddied
afterartiﬁcialventilation.Nineteenothers
were sleeping alone at the time of death,
and 20 were found lying undisturbed
(23). Gill et al. (24) demonstrated that, in
patients with type 1 diabetes, severe hy-
poglycemia was associated with a pro-
longed corrected QT interval. Eight of
those episodes also showed cardiac rate
and rhythm abnormalities.
CEREBRAL ISCHEMIA,
STROKE, AND
DEMENTIA— Severe hypoglycemia
hasbeenknowntoinducefocalneurolog-
ical deﬁcits and transient ischemic at-
tacks, which are reversible with the
correctionofbloodglucose.However,the
questionwhetherhypoglycemiaincreases
the risk for stroke or dementia remains
controversial. Recent evidence suggests
that recurrent or severe hypoglycemia
may predispose to long-term cognitive
dysfunctionanddementia.Whitmeretal.
(25) conducted a longitudinal cohort
study of 16,667 patients with type 2 dia-
betes looking at the relationship between
hypoglycemia and dementia. The study
found that the attributable risk of demen-
tia between individuals with and without
a history of hypoglycemia was 2.4% per
year. Patients with multiple episodes of
hypoglycemia had a graded increase in
dementia risk (25). Conversely, severe
cognitivedysfunctionhasbeenassociated
with increased risk of hypoglycemia. In
the ADVANCE trial (type 2 diabetes), se-
vere cognitive dysfunction increased the
risk of severe hypoglycemia (hazard ratio
2.1) in patients with type 2 diabetes (26).
The Fremantle diabetes study (type 2 di-
abetes) found that dementia was a risk
factor for hypoglycemia. However, hypo-
glycemia itself was not found to increase
theriskofgettingdementia(27).Intype1
diabetes, some small studies show alter-
ations in regional cerebral blood ﬂow in
patients with severe hypoglycemia; how-
ever, these are temporary and reversible
(28).
In the DCCT, despite frequent hypo-
glycemia, intensively treated patients
with type 1 diabetes did not experience
cognitive decline. Some small studies
show alterations in regional cerebral
blood ﬂow in patients with type 1 diabe-
tes with severe hypoglycemia; however,
thesearetemporaryandreversible(28).It
is unclear whether this ﬁnding can be ex-
trapolated to type 2 diabetes. Thus, the
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ROLE OF HYPOGLYCEMIA
IN THE RESULTS OF RECENT
CLINICAL TRIALS— Recently, sev-
erallargerandomizedtrialsevaluatingthe
effects of glycemic control on cardiovas-
cular events have published their results
(29–31).
The ACCORD trial randomized
10,251 participants with a history of car-
diovascular events or signiﬁcant cardio-
vascular risk to a strategy of intensive
glycemic control or standard glycemic
control (29). The ACCORD trial was
halted because of a signiﬁcant increase in
all-cause mortality (22%) and cardiovas-
cular mortality (35%) in the intensive
treatment group. In both the intensive
and standard treatment arms, partici-
pants with severe hypoglycemia had a
higher mortality rate than those without
severe hypoglycemia (29). However, the
association between hypoglycemia and
mortality is much more complex in this
study. The relative risk of death associ-
ated with severe hypoglycemia was 1.28
for the intensive arm versus 2.87 for the
standard arm in spite of larger number of
severe hypoglycemic episodes in the in-
tensive arm. This suggests that severe hy-
poglycemia in a certain subset of patients
may be associated with mortality rather
thanthestrategyoftreatmentused(inten-
sive versus standard). However, these
dataarebasedonposthocanalysis,andthe
truecauseoftheincreasedmortalityinthese
patients may never become obvious. The
subset of patients most prone to the detri-
mental effects of hypoglycemia had several
of the following characteristics: they were
likelytobewomen,AfricanAmerican,older
patients, or patients with a longer duration
of diabetes and have higher A1C and high
albumin-to-creatinine ratio.
VADT randomized 1,791 patients
with type 2 diabetes to an intensive treat-
ment group and a conventional treatment
group (31). At the end of the study, there
wasnosigniﬁcantdifferenceincardiovas-
cular events between the two treatment
arms. As expected, there was an increased
incidence of severe hypoglycemia in the in-
tensive treatment group. Predictors for hy-
poglycemia included increased duration of
diabetes, insulin treatment at baseline, low
BMI, previous cardiovascular events, and
high albumin-to-creatinine ratio.
The ADVANCE study randomized
11,140 participants to an intensive glyce-
mic control arm and a standard glycemic
control arm (30). Although there was an
increased risk of hypoglycemia in the in-
tensive treatment arm, there was no asso-
ciation between hypoglycemia and
cardiovascular mortality (30). One expla-
nation for the discrepancy between this
ﬁnding and that in the ACCORD study is
the extremely low number of patients
(3%) who had severe hypoglycemia in
the intensive treatment arm, during the
course of the entire trial.
It is therefore important to seek out
the similarities and differences in the
study design and patient population of
these studies. Patients in the ADVANCE
trial had a 2- to 3-year shorter duration of
diabetes as well as a lower baseline A1C
than patients in the ACCORD trial. The
number of patients on insulin in the in-
tensive arm versus the standard arm was
77 versus 55% in the ACCORD trail, 90
versus 74% in the VADT, and 41 versus
24% in the ADVANCE trial. Thus, the
ADVANCE trial had a much smaller pro-
portion of patients on insulin than
ACCORD or VADT. This could in part
account for the low level of hypoglycemia
seen in the intensive arm of the ADVANCE
trial (3%) versus the ACCORD trail
(16%) and VADT (21%). The DCCT en-
rolled type 1 diabetic patients on insulin
treatment. In contrast to the UK Diabetes
Prospective Study, VADT, and ACCORD,
the DCCT had a relatively high risk for
severe hypoglycemia in the “conven-
tional” treatment group (0.19 episodes/
patient-year) and a threefold increased
risk in the “intensive” group (0.62 epi-
sodes/patient-year). Interestingly, the
morefrequentseverehypoglycemiainthe
intensive group was not associated with
increased cardiovascular mortality (13) at
later follow-up (1). This indirectly high-
lights the different cardiovascular risk of
hypoglycemia in type 2 versus type 1 dia-
betes. Thus, it is clear that these trials had
different treatment strategies to achieve risk
factor modiﬁcation. Perhaps we can now
appreciate that the strategy used to achieve
riskfactormodiﬁcationisimportantinhow
it affects patient outcomes. Moreover, the
particular strategy’s effect on a risk factor
may not predict its effect on patient out-
comes (32).
HYPOGLYCEMIA AND
INPATIENT GLUCOSE
CONTROL— Hyperglycemia is com-
mon in acutely ill patients and is associ-
ated with an increased morbidity and
mortality (33). This has subsequently led
to a large number of trials using various
intensive insulin protocols to control in-
patient blood glucose. However, results
from these trials have increased the con-
troversy over the risks versus beneﬁt of
tight inpatient glycemic control. Van den
Berghe et al. (34) demonstrated that in-
tensive insulin therapy in critically ill pa-
tients reduced morbidity and mortality.
The DIGAMI (Diabetes Mellitus, Insulin
Glucose Infusion in Acute Myocardial In-
farction)studyfoundthatinsulin-glucose
infusionfollowedbyintensivesubcutane-
ous insulin in diabetic patients with acute
myocardial infarction improved long-
term survival (35). Conversely, the
DIGAMI 2 study did not conﬁrm superi-
ority of insulin versus conventional treat-
ment, but reafﬁrmed the importance of
good glycemic control in prevention of
cardiovascular events (36). The recently
published NICE-SUGAR (Normoglyce-
mia in Intensive Care Evaluation–
Survival Using Glucose Algorithm
Regulation) study found that intensive
glucose control increased mortality
among adults in the ICU (37). The Glu-
cose Insulin in Stroke Trial (GIST)-U.K.
looked at tight control of glucose in pa-
tientswithacutestrokeusinganintensive
insulin infusion protocol and found no
beneﬁt (38). The GIST-UK trial was un-
derpowered to draw any ﬁrm conclu-
sions. However, the sub-analysis of the
mean change in glucose at 24 h showed
that patients who had a decrease in
plasma glucose of 2 mmol/l had a mor-
tality rate of 34 versus 22% for those who
had a 2 mmol/l decrease (38). This
raises the question of hypoglycemia hav-
ing a role in increased mortality in the
inpatient setting.
Some recent studies looking at using
intensive insulin infusions such as the
volume and insulin therapy in severe sep-
sis and septic shock (VISEP) showed that
theincidenceofhypoglycemiawashigher
in the intensively treated group (39). A
study by Kosiborod et al. (40), looking at
16,871 patients admitted with myocar-
dial infarction, found that a J-shaped re-
lationship existed between glucose and
mortality. Incremental increases above
120 mg/dl and incremental declines be-
low 70 mg/dl were found to be strongly
associated with increased mortality. The
slopes of these relationships were even
steeper in patients with diabetes, suggest-
ing hypoglycemia could contribute to in-
creased mortality, especially in diabetic
patients. In another study, a pooled anal-
ysis of over 4,200 patients from various
myocardial infarction intervention stud-
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with hypoglycemia versus 1% of those
who were considered euglycemic (81–
199 mg/dl) (41). In contrast, a sub-
analysis of the DIGAMI 2 data did not
showhypoglycemiatobeanindependent
risk factor for future morbidity or mortal-
ity in patients with type 2 diabetes and
myocardial infarction (42).
Thus,theroleofhypoglycemiaincar-
diovascular mortality in the inpatient set-
ting is still controversial. Much of the
variability in results is due to the different
protocols used, differences in deﬁnition
of hypoglycemia, as well as methodology
of its detection and report, presence or
absence of safeguards against hypoglyce-
miaintheprotocols,localtraininglevelof
the personnel administering the proto-
cols, and selected patient population.
Hence,carefullyconstructedclinicaltrails
to research this question are required.
However, it is prudent to conclude from
the available data that severe hypoglyce-
mia should be avoided as much as possi-
ble in the inpatient setting.
MECHANISMS BY WHICH
HYPOGLYCEMIA MAY
AFFECT CARDIOVASCULAR
EVENTS— Hypoglycemia induces
several counterregulatory responses.
They include a decrease in pancreatic
-cell insulin secretion, an increase in
pancreatic -cell glucagon secretion, an
increased sympathoadrenal response
with acute plasma increase in adrenaline
and norepinephrine (in addition to its ele-
vated tissue turnover), as well as an in-
creased secretion of ACTH/glucocorticoids.
Besides these classical responses, there are
several indirect changes induced by hypo-
glycemia that affect inﬂammatory cytokine
secretion, endothelial function, coagula-
tion, and ﬁbrinolysis. All of these responses
have potential adverse effects on cardiovas-
cular morbidity and mortality and will be
discussed in this section (Fig. 1).
THE SYMPATHOADRENAL
RESPONSE— Hypoglycemia stimu-
lates the release of catecholamines, which
haveprofoundeffectsonthemyocardium
and blood vessels. Catecholamines increase
myocardial contractility, myocardial work-
load, and cardiac output (Fig. 1). These
effects can induce ischemia in the myo-
cardium in patients with coronary vessel
disease (3). The greater oxygen demand is
notmetbecauseoftherigidvessels,butalso
because of endothelial dysfunction with
failure to vasodilate (Fig. 1).
Severalstudieshaveshownthathypo-
glycemia is associated with a signiﬁcant
lengthening of the corrected QT interval
(QTC)insubjectswithandwithoutdiabetes
(10,24). Other electrocardiographic abnor-
malities observed during hypoglycemia in-
clude a decrease in PR interval and
moderate ST segment depressions (10).
Thesechangesarelikelyseenbecauseof
increased catecholamine release during
hypoglycemia, and QTC prolongation
in particular could lead to a high risk of
ventricular tachycardia and sudden
death (43). These changes can be pre-
vented or reversed by  blockade (43).
A few studies suggest that hyperinsu-
linemia and increased secretion of cat-
echolamines may lead to hypokalemia
during hypoglycemia, thus potentiating
cardiac repolarization abnormalities.
These effects can be reversed by  block-
ade and potassium replacement (43).
Cardiovascular autonomic neuropa-
thy or impairment is associated with in-
creased mortality. Effects of antecedent
hypoglycemia on cardiac autonomic reg-
ulationmaycontributetotheoccurrenceof
adverse cardiac events (44). Abnormalities
in high-frequency and low-frequency heart
rate variability have been associated with
hypoglycemia and increases catechol-
amine release (45). However, other stud-
ies did not ﬁnd any associations between
heart rate variability, hypoglycemia, and
increased catecholamine release (10,46).
INFLAMMATION,
COAGULATION, AND
ENDOTHELIAL
DYSFUNCTION DURING
HYPOGLYCEMIA— Inﬂammation
has been associated with cardiovascular
disease and diabetes. Several inﬂamma-
tory markers including C-reactive pro-
tein, interleukin (IL)-6, IL-8, tumor
necrosis factor (TNF)-, and endothe-
lin-1 have been shown to be increased
during hypoglycemia (47,48). This in-
crease in inﬂammatory cytokines could
resultinendothelialinjuryandabnormal-
ities in coagulation, resulting in increased
risk for cardiovascular events (Fig. 1).
Certain growth factor levels such as vas-
cular endothelial growth factor are also
increased locally and in circulation after
an episode of hypoglycemia (49). Fur-
thermore, some cytokines such as IL-1
have been shown to increase the severity
ofhypoglycemia,thusperpetuatingapos-
itive feedback cycle (50).
Figure 1—Mechanisms by which hypoglycemia may affect cardiovascular events. Hypoglycemic
events may trigger inﬂammation by inducing the release of C-reactive protein (CRP), IL-6, and
vascular endothelial growth factor (VEGF). Hypoglycemia also induces increased platelet and
neutrophil activation. The sympathoadrenal response during hypoglycemia increases adrenaline
secretion and may induce arrhythmias and increase cardiac workload. Underlying endothelial
dysfunction leading to decreased vasodilation may also contribute to cardiovascular risk.
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in platelet function and activation of the
ﬁbrinolytic system (51,52). Increased
epinephrine levels lead to an increase in
platelet activation, leukocyte mobiliza-
tion, and blood coagulability (52). Many
ofthesechangescanbereversedbyor
blockade (52).
Recent studies suggest that endothe-
lial function may be compromised during
acute hypoglycemia. Vessel wall stiffness
was found to be increased during hypo-
glycemia in patients with type 1 diabetes
of longer duration than those with a
shorter duration of diabetes (53). Thus,
hypoglycemia may increase the risk of
cardiovascular events, especially in a sub-
set of patients with longer duration of di-
abetes. As discussed before, this has been
suggestedasapossibleexplanationforthe
results of ACCORD and VADT.
Inﬂammation,bloodcomponent,and
functional abnormalities and endothelial
dysfunction are closely interdependent.
These abnormalities could potentially be
aggravating factors that contribute to in-
creased cardiovascular risk with severe
hypoglycemia,especiallywhenappliedto
the subset of patients with preexisting
cardiovascular disease, longer duration of
diabetes, and severe autonomic neuropa-
thy (Fig. 1). However, most of these stud-
ies are short-duration acute observations
andthelong-termeffectsofhypoglycemia
on inﬂammation, coagulation, and endo-
thelial dysfunction are largely unknown
and need to be studied.
CONCLUSIONS — Thereviewofthe
literature and results from large random-
ized trials suggest that severe hypoglyce-
mia is common during intensive therapy
in type 1 and type 2 diabetes. This is true
in the outpatient setting as well as the in-
patientsetting.Althoughsmallerobserva-
tional and epidemiological studies
suggest an association between hypogly-
cemia and cardiovascular events, there is
currentlynoevidenceforcausality.Larger
clinical trials looking speciﬁcally at this
questionarerequired.Themechanismsthat
might be involved also need to be deter-
mined further. Our challenge in these
patients is to lower blood glucose to near-
normal values to lower the risk for long-
term complications, but at the same time
minimize hypoglycemia- and hypoglyce-
mia-associated morbidity and mortality.
Acknowledgments— V.F. has received re-
searchsupportfromGlaxoSmithKline,Novar-
tis, Novo Nordisk, Takeda, Pﬁzer, sanoﬁ-
aventis, Eli Lilly, and the American Diabetes
Association.Hehasalsoreceivedhonorariafor
consulting and lectures from GlaxoSmith-
Kline,Novartis,NovoNordisk,Takeda,Pﬁzer,
sanoﬁ-aventis, Eli Lilly, and Daiichi Sankyo.
C.V.D. has received honoraria from Novo
Nordisk and Takeda for consulting. No other
potential conﬂicts of interest relevant to this
article were reported.
References
1. GoreMO,McGuireDK.The10-yearpost-
trial follow-up of the United Kingdom
ProspectiveDiabetesStudy(UKPDS):car-
diovascular observations in context. Diab
Vasc Dis Res 2009;6:53–55
2. Keen H. The Diabetes Control and Com-
plications Trial (DCCT). Health Trends
1994;26:41–43
3. Egeli ES, Berkmen R. Action of hypogly-
cemia on coronary insufﬁciency and
mechanism of ECG alterations. Am
Heart J 1960;59:527–540
4. FismanEZ,MotroM,TenenbaumA,Leor
J, Boyko V, Mandelzweig L, Sherer Y,
Adler Y, Behar S. Is hypoglycaemia a
marker for increased long-term mortality
risk in patients with coronary artery dis-
ease? An 8-year follow-up. Eur J Cardio-
vasc Prev Rehabil 2004;11:135–143
5. Judson WE, Hollander W. The effects of
insulin-induced hypoglycemia in patients
with angina pectoris: before and after in-
travenous hexamethonium. Am Heart J
1956;52:198–209
6. SkylerJS,BergenstalR,BonowRO,BuseJ,
Deedwania P, Gale EA, Howard BV, Kirk-
man MS, Kosiborod M, Reaven P, Sher-
win RS, American Diabetes Association,
American College of Cardiology Founda-
tion, American Heart Association. Inten-
sive glycemic control and the prevention
of cardiovascular events: implications of
theACCORD,ADVANCE,andVADiabe-
tes Trials: a position statement of the
American Diabetes Association and a Sci-
entiﬁc Statement of the American College
of Cardiology Foundation and the Amer-
ican Heart Association. J Am Coll Cardiol
2009;53:298–304
7. American Diabetes Association. Standards
ofmedicalcareindiabetes—2010.Diabetes
Care 2010;33(Suppl. 1):11–61
8. Cryer PE. Hypoglycemia: still the limiting
factor in the glycemic management of di-
abetes. Endocr Pract 2008;14:750–756
9. Rossetti P, Porcellati F, Bolli GB, Fanelli
CG. Prevention of hypoglycemia while
achieving good glycemic control in type
1 diabetes: the role of insulin analogs.
Diabetes Care 2008;31(Suppl. 2):113–
120
10. Laitinen T, Lyyra-Laitinen T, Huopio H,
VauhkonenI,HalonenT,HartikainenJ,Ni-
skanen L, Laakso M. Electrocardiographic
alterations during hyperinsulinemic hypo-
glycemiainhealthysubjects.AnnNoninva-
sive Electrocardiol 2008;13:97–105
11. Sherwin RS. Bringing light to the dark side
of insulin: a journey across the blood-brain
barrier. Diabetes 2008;57:2259–2268
12. Cryer PE: Hypoglycemia in Diabetes: Patho-
physiology, Prevalence and Prevention. Alex-
andria, VA, American Diabetes Association,
2009
13. Hypoglycemia intheDiabetes Control and
Complications Trial. The Diabetes Control
and Complications Trial Research Group.
Diabetes 1997;46:271–286
14. Holman RR, Farmer AJ, Davies MJ, Levy
JC, Darbyshire JL, Keenan JF, Paul SK, 4-T
Study Group. Three-year efﬁcacy of com-
plex insulin regimens in type 2 diabetes.
N Engl J Med 2009;361:1736–1747
15. UK Hypoglycaemia Study Group. Risk of
hypoglycaemia in types 1 and 2 diabetes:
effectsoftreatmentmodalitiesandtheirdu-
ration. Diabetologia 2007;50:1140–1147
16. Shorr RI, Ray WA, Daugherty JR, Grifﬁn
MR. Incidence and risk factors for serious
hypoglycemia in older persons using in-
sulin or sulfonylureas. Arch Intern Med
1997;157:1681–1686
17. DonnellyLA,MorrisAD,FrierBM,EllisJD,
Donnan PT, Durrant R, Band MM, Reekie
G,LeeseGP,DARTS/MEMOCollaboration.
Frequency and predictors of hypoglycae-
mia in type 1 and insulin-treated Type 2
diabetes: a population-based study. Diabet
Med 2005;22:749–755
18. Miller CD, Phillips LS, Ziemer DC, Gallina
DL, Cook CB, El-Kebbi IM. Hypoglycemia
in patients with type 2 diabetes mellitus.
Arch Intern Med 2001;161:1653–1659
19. Strouse SSS, Katz LN, Rubinﬁeld SH.
Treatment of older diabetic patients with
cardiovascular disease. JAMA 1932;98:
1703–1706
20. Abraira C, Colwell J, Nuttall F, Sawin CT,
Henderson W, Comstock JP, Emanuele
NV, Levin SR, Pacold I, Lee HS. Cardiovas-
cular events and correlates in the Veterans
Affairs Diabetes Feasibility Trial. Veterans
Affairs Cooperative Study on Glycemic
Control and Complications in Type II Dia-
betes. Arch Intern Med 1997;157:181–188
21. BARI 2D Study Group, Frye RL, August P,
Brooks MM, Hardison RM, Kelsey SF,
MacGregor JM, Orchard TJ, Chaitman BR,
Genuth SM, Goldberg SH, Hlatky MA,
Jones TL, Molitch ME, Nesto RW, Sako EY,
SobelBE.Arandomizedtrialoftherapiesfor
type 2 diabetes and coronary artery disease.
N Engl J Med 2009;360:2503–2515
22. DesouzaC,SalazarH,CheongB,MurgoJ,
Fonseca V. Association of hypoglycemia
and cardiac ischemia: a study based on
continuous monitoring. Diabetes Care
2003;26:1485–1489
23. Tattersall RB, Gill GV. Unexplained
deaths of type 1 diabetic patients. Diabet
Med 1991;8:49–58
24. GillGV,WoodwardA,CassonIF,Weston
PJ. Cardiac arrhythmia and nocturnal hy-
Desouza, Bolli, and Fonseca
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 6, JUNE 2010 1393poglycaemia in type 1 diabetes: the ‘dead
in bed’ syndrome revisited. Diabetologia
2009;52:42–45
25. Whitmer RA, Karter AJ, Yaffe K, Quesen-
berry CP Jr, Selby JV. Hypoglycemic epi-
sodes and risk of dementia in older
patients with type 2 diabetes mellitus.
JAMA 2009;301:1565–1572
26. de Galan BE, Zoungas S, Chalmers J,
Anderson C, Dufouil C, Pillai A, Cooper
M, Grobbee DE, Hackett M, Hamet P,
Heller SR, Lisheng L, Macmahon S, Man-
cia G, Neal B, Pan CY, Patel A, Poulter N,
Travert F, Woodward M. Cognitive func-
tion and risks of cardiovascular disease
and hypoglycaemia in patients with type
2 diabetes: the Action in Diabetes and
VascularDisease:PreteraxandDiamicron
Modiﬁed Release Controlled Evaluation
(ADVANCE) trial. Diabetologia 2009;52:
2328–2336
27. BruceDG,DavisWA,CaseyGP,Clarnette
RM, Brown SG, Jacobs IG, Almeida OP,
Davis TM. Severe hypoglycaemia and
cognitive impairment in older patients
with diabetes: the Fremantle Diabetes
Study. Diabetologia 2009;52:1808–1815
28. MacLeod KM, Hepburn DA, Deary IJ,
Goodwin GM, Dougall N, Ebmeier KP,
Frier BM. Regional cerebral blood ﬂow in
IDDM patients: effects of diabetes and of
recurrentseverehypoglycaemia.Diabeto-
logia 1994;37:257–263
29. Action to Control Cardiovascular Risk in
Diabetes Study Group, Gerstein HC,
Miller ME, Byington RP, Goff DC Jr, Big-
ger JT, Buse JB, Cushman WC, Genuth S,
Ismail-Beigi F, Grimm RH Jr, Probstﬁeld
JL, Simons-Morton DG, Friedewald WT.
Effects of intensive glucose lowering in
type 2 diabetes. N Engl J Med 2008;358:
2545–2559
30. ADVANCE Collaborative Group, Patel A,
MacMahon S, Chalmers J, Neal B, Billot L,
Woodward M, Marre M, Cooper M, Glas-
ziou P, Grobbee D, Hamet P, Harrap S,
Heller S, Liu L, Mancia G, Mogensen CE,
Pan C, Poulter N, Rodgers A, Williams B,
BompointS,deGalanBE,JoshiR,TravertF.
Intensive blood glucose control and vas-
cular outcomes in patients with type 2
diabetes. N Engl J Med 2008;358:2560–
2572
31. Duckworth W, Abraira C, Moritz T, Reda
D, Emanuele N, Reaven PD, Zieve FJ,
Marks J, Davis SN, Hayward R, Warren
SR, Goldman S, McCarren M, Vitek ME,
HendersonWG,HuangGD,VADTInves-
tigators. Glucose control and vascular
complications in veterans with type 2 di-
abetes. N Engl J Med 2009;360:129–139
32. Krumholz HM, Lee TH. Redeﬁning qual-
ity: implications of recent clinical trials.
N Engl J Med 2008;358:2537–2539
33. Capes SE, Hunt D, Malmberg K, Gerstein
HC. Stress hyperglycaemia and increased
riskofdeathaftermyocardialinfarctionin
patients with and without diabetes: a sys-
tematic overview. Lancet 2000;355:773–
778
34. VandenBergheG,WilmerA,HermansG,
Meersseman W, Wouters PJ, Milants I,
VanWijngaerdenE,BobbaersH,Bouillon
R.Intensiveinsulintherapyinthemedical
ICU. N Engl J Med 2006;354:449–461
35. Malmberg K. Prospective randomised
studyofintensiveinsulintreatmentonlong
term survival after acute myocardial infarc-
tion in patients with diabetes mellitus.
DIGAMI (Diabetes Mellitus, Insulin Glu-
cose Infusion in Acute Myocardial Infarc-
tion) Study Group. BMJ 1997;314:1512–
1515
36. Malmberg K,Ryde ´n L, Wedel H, Birkeland
K, Bootsma A, Dickstein K, Efendic S,
FisherM,HamstenA,HerlitzJ,Hildebrandt
P,MacLeodK,LaaksoM,Torp-PedersenC,
Waldenstro ¨m A, DIGAMI 2 Investigators.
Intensemetaboliccontrolbymeansofinsu-
lin in patients with diabetes mellitus and
acutemyocardialinfarction(DIGAMI2):ef-
fects on mortality and morbidity. Eur
Heart J 2005;26:650–661
37. NICE-SUGARStudyInvestigators,FinferS,
Chittock DR, Su SY, Blair D, Foster D, Dh-
ingraV,BellomoR,CookD,DodekP,Hen-
derson WR, He ´bert PC, Heritier S, Heyland
DK, McArthur C, McDonald E, Mitchell I,
Myburgh JA, Norton R, Potter J, Robinson
BG,RoncoJJ.Intensiveversusconventional
glucose control in critically ill patients.
N Engl J Med 2009;360:1283–1297
38. Gray CS, Hildreth AJ, Sandercock PA,
O’ConnellJE,JohnstonDE,CartlidgeNE,
Bamford JM, James OF, Alberti KG, GIST
Trialists Collaboration. Glucose-potassi-
um-insulin infusions in the management
of post-stroke hyperglycaemia: the UK
Glucose Insulin in Stroke Trial (GIST-
UK). Lancet Neurol 2007;6:397–406
39. Brunkhorst FM, Engel C, Bloos F, Meier-
Hellmann A, Ragaller M, Weiler N, Mo-
erer O, Gruendling M, Oppert M, Grond
S, Olthoff D, Jaschinski U, John S, Ros-
saint R, Welte T, Schaefer M, Kern P, Ku-
hnt E, Kiehntopf M, Hartog C, Natanson
C, Loefﬂer M, Reinhart K, German Com-
petence Network Sepsis (SepNet). Inten-
sive insulin therapy and pentastarch
resuscitation in severe sepsis. N Engl
J Med 2008;358:125–139
40. Kosiborod M, Inzucchi SE, Krumholz
HM, Xiao L, Jones PG, Fiske S, Masoudi
FA,MarsoSP,SpertusJA.Glucometricsin
patients hospitalized with acute myocar-
dial infarction: deﬁning the optimal out-
comes-based measure of risk. Circulation
2008;117:1018–1027
41. Pinto DS, Skolnick AH, Kirtane AJ, Mur-
phy SA, Barron HV, Giugliano RP, Can-
non CP, Braunwald E, Gibson CM, TIMI
Study Group. U-shaped relationship of
blood glucose with adverse outcomes
among patients with ST-segment eleva-
tionmyocardialinfarction.JAmCollCar-
diol 2005;46:178–180
42. Mellbin LG, Malmberg K, Waldenstro ¨m
A, Wedel H, Ryde ´n L, DIGAMI 2 Investi-
gators. Prognostic implications of hypo-
glycaemicepisodesduringhospitalisation
for myocardial infarction in patients with
type2diabetes:areportfromtheDIGAMI
2 trial. Heart 2009;95:721–727
43. Robinson RT, Harris ND, Ireland RH, Lee
S, Newman C, Heller SR. Mechanisms of
abnormal cardiac repolarization during
insulin-induced hypoglycemia. Diabetes
2003;52:1469–1474
44. Adler GK, Bonyhay I, Failing H, Waring E,
Dotson S, Freeman R. Antecedent hypogly-
cemia impairs autonomic cardiovascular
function:implicationsforrigorousglycemic
control. Diabetes 2009;58:360–366
45. Vlcek M, Radikova Z, Penesova A, Kvet-
nansky R, Imrich R. Heart rate variability
andcatecholaminesduringhypoglycemia
and orthostasis. Auton Neurosci 2008;
143:53–57
46. Koivikko ML, Karsikas M, Salmela PI,
TapanainenJS,RuokonenA,Seppa ¨nenT,
Huikuri HV, Perkio ¨ma ¨ki JS. Effects of
controlled hypoglycaemia on cardiac re-
polarisation in patients with type 1 diabe-
tes. Diabetologia 2008;51:426–435
47. Galloway PJ, Thomson GA, Fisher BM,
Semple CG. Insulin-induced hypoglyce-
mia induces a rise in C-reactive protein.
Diabetes Care 2000;23:861–862
48. RazaviNematollahiL,KitabchiAE,Kitab-
chi AE, Stentz FB, Wan JY, Larijani BA,
Tehrani MM, Gozashti MH, Omidfar K,
Taheri E. Proinﬂammatory cytokines in
response to insulin-induced hypoglyce-
micstressinhealthysubjects.Metabolism
2009;58:443–448
49. Dantz D, Bewersdorf J, Fruehwald-Schul-
tesB,KernW,JelkmannW,BornJ,Fehm
HL,PetersA.Vascularendothelialgrowth
factor: a novel endocrine defensive re-
sponse to hypoglycemia. J Clin Endocri-
nol Metab 2002;87:835–840
50. DelReyA,RoggeroE,RandolfA,Mahuad
C, McCann S, Rettori V, Besedovsky HO.
IL-1 resets glucose homeostasis at central
levels.ProcNatlAcadSciUSA2006;103:
16039–16044
51. Dalsgaard-Nielsen J, Madsbad S, Hilsted
J. Changes in platelet function, blood co-
agulation and ﬁbrinolysis during insulin-
induced hypoglycaemia in juvenile
diabetics and normal subjects. Thromb
Haemost 1982;47:254–258
52. Fisher BM, Hepburn DA, Smith JG, Frier
BM. Responses of peripheral blood cells
to acute insulin-induced hypoglycaemia
in humans: effect of alpha-adrenergic
blockade. Horm Metab Res Suppl 1992;
26:109–110
53. Sommerﬁeld AJ, Wilkinson IB, Webb DJ,
Frier BM. Vessel wall stiffness in type 1 dia-
betes and the central hemodynamic effects
of acute hypoglycemia. Am J Physiol Endo-
crinol Metab 2007;293:E1274–E1279
Hypoglycemia and cardiovascular events
1394 DIABETES CARE, VOLUME 33, NUMBER 6, JUNE 2010 care.diabetesjournals.org